<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05090683</url>
  </required_header>
  <id_info>
    <org_study_id>100820</org_study_id>
    <nct_id>NCT05090683</nct_id>
  </id_info>
  <brief_title>Evaluation of a Mind-body Based Application for the Treatment of Chronic/Persistent Pain.</brief_title>
  <official_title>Evaluation of a Mind-body Based Application for the Treatment of Chronic/Persistent Pain.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of the Fraser Valley</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of the Fraser Valley</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      We are investigating the effects of a mind-body based mobile application on the experience of&#xD;
      chronic pain.&#xD;
&#xD;
      Participants meeting our criteria for chronic pain (confirmed via self-report) will complete&#xD;
      an online baseline questionnaire. Eligible participants will be enrolled in the study and&#xD;
      randomized into control (usual care, waitlisted) or intervention group (6-week mind-body&#xD;
      based mobile application intervention). Randomization will be stratified by pain intensity&#xD;
      and gender using computer-generated block randomization to create varying block sizes of 4&#xD;
      and 8. We will run the trial in multiple cohorts in series to obtain desired sample size.&#xD;
&#xD;
      All participants will complete online questionnaires at baseline and post-intervention at 6&#xD;
      weeks that measure pain intensity, interference with daily living, pain perceptions, mental&#xD;
      health outcomes, and medication use. Participants will also complete weekly questionnaires on&#xD;
      weeks 2 to 6 to gauge frequency of application usage (intervention) or other pain treatments&#xD;
      (control). Participants in the intervention group will be asked to repeat the follow-up&#xD;
      questionnaire at 12-weeks.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">October 15, 2021</start_date>
  <completion_date type="Anticipated">October 15, 2022</completion_date>
  <primary_completion_date type="Anticipated">August 1, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Participants will be randomized into one of two groups: control (usual care, waitlisted) or intervention group (6-week mind-body mobile application use). Randomization will be stratified on pain intensity and gender using computer generated block randomization to create varying block sizes of 4 and 8.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
    <masking_description>Participants in the control group will be aware that they have are serving as controls that have been wait-listed for access to the mobile application.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Brief Pain Inventory-short form (BPI-SF)</measure>
    <time_frame>6 weeks</time_frame>
    <description>Measures self reported pain intensity (on average); Pain interference</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in PROMIS Pain Intensity short form</measure>
    <time_frame>6 weeks</time_frame>
    <description>Measures self reported pain intensity over 7 days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in PROMIS Pain Interference short form 8a</measure>
    <time_frame>6 and 12 weeks</time_frame>
    <description>Measures self reported pain interference in daily activities (over 7 days)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Pain Catastrophizing Questionnaire (PCS)</measure>
    <time_frame>6 and 12 weeks</time_frame>
    <description>Measures thoughts and perceptions of pain</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in DASS-21 (Depression, Anxiety, and Stress Scale)</measure>
    <time_frame>6 and 12 weeks</time_frame>
    <description>Measures self reported emotional states</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Quality of Life Short Form 12 (SF-12)</measure>
    <time_frame>6 and 12 weeks</time_frame>
    <description>Measures self-reported impact of health on daily life</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Brief Pain Inventory-short form (BPI-SF)</measure>
    <time_frame>12 weeks</time_frame>
    <description>Measures self reported pain intensity; Pain interference (over past 24 hours)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in PROMIS Pain Intensity short form</measure>
    <time_frame>12 weeks</time_frame>
    <description>Measures self reported pain intensity over 7 days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Medication use (daily)</measure>
    <time_frame>6 weeks</time_frame>
    <description>Self-reported quantify of medication used (dosage, number of pills in 24 hours)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Medication use (occasional)</measure>
    <time_frame>6 weeks</time_frame>
    <description>Self-reported quantify of medication used (dosage, number of pills in 7 days)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Chronic Pain</condition>
  <condition>Migraine</condition>
  <condition>Chronic Pain Syndrome</condition>
  <arm_group>
    <arm_group_label>Mind-body mobile application</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants are asked to engage with a user-guided mobile application (app) that employs mind-based techniques that include: expressive writing, meditation, cognitive behavioural therapy, and pain education. The app also includes access to podcasts that focus on pain counselling and pain education.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Participants are asked to continue with usual care for pain treatments. They are asked not to start any new forms of treatment.</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Mind-body mobile application</intervention_name>
    <description>Self-directed; Study team will recommend daily use of mobile app for 6 weeks with a minimum of 4 times/week usage of mobile app for 6 weeks. Frequency will be monitored via weekly surveys.</description>
    <arm_group_label>Mind-body mobile application</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Participants aged 19 to 75 years with chronic pain.&#xD;
&#xD;
          -  chronic pain is defined as having non-malignant chronic or persistent pain for at&#xD;
             least 6 months.&#xD;
&#xD;
          -  Participants must experience pain at least half the days in the last 6 months.&#xD;
&#xD;
          -  Pain can include bodily pain or head (migraine) pain.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Individuals reporting a cognitive impairment that can interfere with completing&#xD;
             questionnaires and using a mobile application.&#xD;
&#xD;
          -  Individuals reporting any of the following psychiatric illness: schizophrenia,&#xD;
             dissociative or personality disorders, bipolar disorder.&#xD;
&#xD;
          -  Individuals reporting any of the following medical conditions: metastatic cancer,&#xD;
             rheumatoid arthritis, lupus, scleroderma, polymyositis.&#xD;
&#xD;
          -  Individuals reporting substance use disorder (within the last 6 months).&#xD;
&#xD;
          -  Individuals that have previously used mind-body apps for the treatment of chronic&#xD;
             pain.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Cynthia J Thomson, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of the Fraser Valley</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Cynthia J Thomson, PhD</last_name>
    <phone>604-792-0025</phone>
    <phone_ext>2518</phone_ext>
    <email>cynthia.thomson@ufv.ca</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of the Fraser Valley</name>
      <address>
        <city>Chilliwack</city>
        <state>British Columbia</state>
        <zip>V2R0N3</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cynthia J Thomson, PhD</last_name>
      <phone>604-792-0025</phone>
      <phone_ext>2518</phone_ext>
      <email>cynthia.thomson@ufv.ca</email>
    </contact>
    <investigator>
      <last_name>Luisa V Giles, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <reference>
    <citation>Ashar YK, Gordon A, Schubiner H, Uipi C, Knight K, Anderson Z, Carlisle J, Polisky L, Geuter S, Flood TF, Kragel PA, Dimidjian S, Lumley MA, Wager TD. Effect of Pain Reprocessing Therapy vs Placebo and Usual Care for Patients With Chronic Back Pain: A Randomized Clinical Trial. JAMA Psychiatry. 2021 Sep 29. doi: 10.1001/jamapsychiatry.2021.2669. [Epub ahead of print]</citation>
    <PMID>34586357</PMID>
  </reference>
  <reference>
    <citation>Pfeifer AC, Uddin R, Schröder-Pfeifer P, Holl F, Swoboda W, Schiltenwolf M. Mobile Application-Based Interventions for Chronic Pain Patients: A Systematic Review and Meta-Analysis of Effectiveness. J Clin Med. 2020 Nov 5;9(11). pii: E3557. doi: 10.3390/jcm9113557. Review.</citation>
    <PMID>33167300</PMID>
  </reference>
  <reference>
    <citation>Morone NE, Greco CM. Mind-body interventions for chronic pain in older adults: a structured review. Pain Med. 2007 May-Jun;8(4):359-75. Review.</citation>
    <PMID>17610459</PMID>
  </reference>
  <reference>
    <citation>Treede RD, Rief W, Barke A, Aziz Q, Bennett MI, Benoliel R, Cohen M, Evers S, Finnerup NB, First MB, Giamberardino MA, Kaasa S, Kosek E, Lavand'homme P, Nicholas M, Perrot S, Scholz J, Schug S, Smith BH, Svensson P, Vlaeyen JWS, Wang SJ. A classification of chronic pain for ICD-11. Pain. 2015 Jun;156(6):1003-1007. doi: 10.1097/j.pain.0000000000000160.</citation>
    <PMID>25844555</PMID>
  </reference>
  <reference>
    <citation>Borm GF, Fransen J, Lemmens WA. A simple sample size formula for analysis of covariance in randomized clinical trials. J Clin Epidemiol. 2007 Dec;60(12):1234-8. Epub 2007 Jun 6.</citation>
    <PMID>17998077</PMID>
  </reference>
  <reference>
    <citation>Schopflocher D, Taenzer P, Jovey R. The prevalence of chronic pain in Canada. Pain Res Manag. 2011 Nov-Dec;16(6):445-50.</citation>
    <PMID>22184555</PMID>
  </reference>
  <reference>
    <citation>GBD 2016 Disease and Injury Incidence and Prevalence Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet. 2017 Sep 16;390(10100):1211-1259. doi: 10.1016/S0140-6736(17)32154-2. Erratum in: Lancet. 2017 Oct 28;390(10106):e38.</citation>
    <PMID>28919117</PMID>
  </reference>
  <reference>
    <citation>Ware J Jr, Kosinski M, Keller SD. A 12-Item Short-Form Health Survey: construction of scales and preliminary tests of reliability and validity. Med Care. 1996 Mar;34(3):220-33.</citation>
    <PMID>8628042</PMID>
  </reference>
  <reference>
    <citation>Gatchel RJ, Peng YB, Peters ML, Fuchs PN, Turk DC. The biopsychosocial approach to chronic pain: scientific advances and future directions. Psychol Bull. 2007 Jul;133(4):581-624. Review.</citation>
    <PMID>17592957</PMID>
  </reference>
  <reference>
    <citation>Lovibond PF, Lovibond SH. The structure of negative emotional states: comparison of the Depression Anxiety Stress Scales (DASS) with the Beck Depression and Anxiety Inventories. Behav Res Ther. 1995 Mar;33(3):335-43.</citation>
    <PMID>7726811</PMID>
  </reference>
  <reference>
    <citation>Cleeland CS, Ryan KM. Pain assessment: global use of the Brief Pain Inventory. Ann Acad Med Singap. 1994 Mar;23(2):129-38. Review.</citation>
    <PMID>8080219</PMID>
  </reference>
  <reference>
    <citation>Osman A, Barrios FX, Kopper BA, Hauptmann W, Jones J, O'Neill E. Factor structure, reliability, and validity of the Pain Catastrophizing Scale. J Behav Med. 1997 Dec;20(6):589-605.</citation>
    <PMID>9429990</PMID>
  </reference>
  <reference>
    <citation>Kean J, Monahan PO, Kroenke K, Wu J, Yu Z, Stump TE, Krebs EE. Comparative Responsiveness of the PROMIS Pain Interference Short Forms, Brief Pain Inventory, PEG, and SF-36 Bodily Pain Subscale. Med Care. 2016 Apr;54(4):414-21. doi: 10.1097/MLR.0000000000000497.</citation>
    <PMID>26807536</PMID>
  </reference>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>October 13, 2021</study_first_submitted>
  <study_first_submitted_qc>October 13, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 25, 2021</study_first_posted>
  <last_update_submitted>October 13, 2021</last_update_submitted>
  <last_update_submitted_qc>October 13, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 25, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>chronic pain</keyword>
  <keyword>mind-body</keyword>
  <keyword>mobile application</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Chronic Pain</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>October 12, 2021</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/83/NCT05090683/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

